Cinclus Pharma Holding AB (publ) (STO:CINPHA)

Market Cap	799.52M
Revenue (ttm)	4.58M
Net Income (ttm)	-164.81M
Shares Out	46.54M
EPS (ttm)	-3.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	196,310
Average Volume	48,559
Open	18.20
Previous Close	18.40
Day's Range	18.10 - 19.30
52-Week Range	9.31 - 35.30
Beta	n/a
RSI	54.25
Earnings Date	Aug 20, 2025

About Enfusion

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Employees: 18
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CINPHA

Financial Performance

In 2024, Cinclus Pharma Holding AB's revenue was 4.58 million, a decrease of -23.14% compared to the previous year's 5.96 million. Losses were -168.03 million, -21.89% less than in 2023.